Former Love Island contestant Maxwell Samuda has become the first man to publicly connect his health issues, including reproductive problems, to the pregnancy drug Diethylstilbestrol (DES), which was taken by his grandmother in the 1970s. This revelation highlights the ongoing impact of a synthetic oestrogen prescribed to hundreds of thousands of women decades ago.
Family Health Concerns Linked to DES Exposure
Maxwell Samuda, aged 26 and known for appearing on the ninth season of ITV's Love Island, has spoken out about his struggles, believing they stem from DES exposure. His mother, Natalie Samuda, 50, and grandmother, Maureen Day, 78, also report health conditions such as breast cancer and autoimmune issues that they attribute to the drug. The family's case underscores the intergenerational effects of DES, which was widely used from the 1940s to the 1970s to prevent miscarriages.
Historical Use and Risks of Diethylstilbestrol
Diethylstilbestrol, a synthetic oestrogen, was administered to approximately 300,000 women during its peak usage period. Initially promoted as a safe treatment for pregnancy complications, it was later linked to various cancers and reproductive abnormalities in both the women who took it and their descendants. Despite US regulators advising against its use in pregnant women in 1971, DES continued to be prescribed in Europe until the late 1970s, leaving a legacy of health issues across generations.
Calls for Action and Support from Campaign Groups
The Samuda family is supporting efforts by the campaign group DES Justice UK (DJUK), which is advocating for a full public inquiry into the drug's impact. Their demands include the establishment of a compensation scheme for affected individuals and the implementation of an NHS screening programme to monitor and address DES-related health problems. This push aims to provide recognition and support for those still suffering from the consequences of this historical medical practice.
As awareness grows, cases like Maxwell Samuda's bring renewed attention to the need for accountability and healthcare measures for DES victims. The family's public stance could inspire others to come forward and seek justice, potentially leading to broader policy changes in the UK's health system.
